Rare form of eye stroke that causes blindness now linked to Ozempic and Wegovy
A study links Ozempic and Wegovy to increased risk of rare blindness (NAION) in diabetes and obesity patients. While causation isn't confirmed, caution and consultation with healthcare providers are advised. Novo Nordisk prioritizes patient safety.
Read original article
A recent study suggests that individuals taking the weight loss and diabetes drugs Ozempic or Wegovy may have an increased risk of developing a rare form of blindness known as non-arteritic anterior ischemic optic neuropathy (NAION). The study observed a higher likelihood of NAION diagnosis in patients with diabetes or obesity who were prescribed semaglutide medications. While the study does not definitively prove causation, it highlights a potential association that warrants further investigation. Despite the elevated risk, experts advise that the benefits of these medications in treating diabetes and obesity outweigh the potential risks of NAION. Patients currently using or considering these drugs are encouraged to consult with their healthcare providers to discuss the risks and benefits, especially if they have preexisting optic nerve issues. The drug manufacturer, Novo Nordisk, emphasizes patient safety and is actively monitoring and researching any potential side effects related to these medications.
Related
Study identifies first drug therapy for sleep apnea
Researchers at UC San Diego found tirzepatide, a diabetes drug, promising for treating sleep apnea. The study on 469 participants worldwide showed reduced breathing interruptions, weight loss, and improved heart health. Tirzepatide may offer a new OSA treatment option.
A 5,2 Intermittent Fasting Meal Replacement Diet for Adults with Diabetes
A randomized trial compared 5:2 intermittent fasting with metformin and empagliflozin in diabetic adults. Results showed improved glycemic control with reduced HbA1c levels and fasting glucose, suggesting potential benefits for diabetes management.
Hims & Hers Selling GLP-1 Injection That’s Not FDA Approved, From Shady Supplier
Hims & Hers sells non-FDA approved weight loss drug through loophole, raising concerns about patient safety, legality, and supplier's history of fraud. Executives sold shares amid risks of legal consequences.
The Limited Value of Multivitamin Supplements
A study in JAMA Network Open found multivitamin supplements did not reduce mortality risk and could increase it by 4%. Obtaining vitamins from food is preferred, with some exceptions for specific health conditions.
'Skinny jabs': weight-loss drugs set for new boom as generic versions emerge
Medicines like Wegovy and Saxenda, known as "skinny jabs," are gaining popularity for weight loss. Generic versions, like Teva's generic Victoza, are expected to increase accessibility and affordability, benefiting a broader population. Novo Nordisk invests $4 billion to meet rising demand.
3 commentsRelated
Study identifies first drug therapy for sleep apnea
Researchers at UC San Diego found tirzepatide, a diabetes drug, promising for treating sleep apnea. The study on 469 participants worldwide showed reduced breathing interruptions, weight loss, and improved heart health. Tirzepatide may offer a new OSA treatment option.
A 5,2 Intermittent Fasting Meal Replacement Diet for Adults with Diabetes
A randomized trial compared 5:2 intermittent fasting with metformin and empagliflozin in diabetic adults. Results showed improved glycemic control with reduced HbA1c levels and fasting glucose, suggesting potential benefits for diabetes management.
Hims & Hers Selling GLP-1 Injection That’s Not FDA Approved, From Shady Supplier
Hims & Hers sells non-FDA approved weight loss drug through loophole, raising concerns about patient safety, legality, and supplier's history of fraud. Executives sold shares amid risks of legal consequences.
The Limited Value of Multivitamin Supplements
A study in JAMA Network Open found multivitamin supplements did not reduce mortality risk and could increase it by 4%. Obtaining vitamins from food is preferred, with some exceptions for specific health conditions.
'Skinny jabs': weight-loss drugs set for new boom as generic versions emerge
Medicines like Wegovy and Saxenda, known as "skinny jabs," are gaining popularity for weight loss. Generic versions, like Teva's generic Victoza, are expected to increase accessibility and affordability, benefiting a broader population. Novo Nordisk invests $4 billion to meet rising demand.